Veracyte宣布Prosigna乳腺癌复发风险检测获Medicare(MolDX)报销覆盖
官方一手新闻稿、支付覆盖为真实正向准入催化,标的唯一且流动性好;但增量短期财务量级有限、覆盖回溯生效近两个月存在部分price-in,故只给小仓,盘前已涨约1.9%,限价控制追高。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
分时走势
做多 VCYT.US Veracyte, Inc.
5 个交易日均已收盘,数据完整 · 美股含盘前盘后(灰底:美东 04:00 至收盘后 4 小时)
- 发布 10-16 21:20 北京(美东 10-16 09:20)
- 抓取 10-16 21:21 北京(美东 10-16 09:21)
- 决策 10-16 21:23 北京(美东 10-16 09:23)
- 入场 10-16 21:30 北京(美东 10-16 09:30) · 盘前首笔 @45.17
- 离场 10-19 21:30 北京(美东 10-19 09:30) · 开盘 @43.70
时间轴只含交易时段(午休、隔夜已压缩);横轴为北京时间,悬停看当地时间;蓝虚线 = 纸面入场价;建仓日图红线在昨收上方、绿线在下方
成交明细 · 纸面
做多 VCYT.US Veracyte, Inc.
| 收益状态 | -3.37% 已平仓 |
|---|---|
| 进场成交 | 2026-10-16 · 盘前首笔 · 10-16 21:30 北京 · @45.1686 |
| 离场成交 | 2026-10-19 · 开盘 · @43.7 |
| 毛收益 | -3.25% |
| 成本 | +0.12% |
| 净收益 | -3.37% |
| 计入收益 | -3.37% |
| 建仓日 | 2026-10-16 · 进场不早于新闻时刻 + 2 分钟 |
收益口径 event_time_plus_2min_10min_walk_open_topup_to_next_open_exchange_calendar_fill_model_local_notional_v9 · method_id m8db1cbc8f2d · 截至 2026-10-28 02:20
研究档案
结论摘要
Veracyte新上市的Prosigna乳腺癌检测拿到Medicare MolDX报销,消除65岁以上人群支付障碍,配合III期OPTIMA数据利好检测放量;属方向明确但短期量级有限的准入催化,盘前小幅反应,以小仓参与。
消息传播链
- 公司2026-10-16发布新闻稿确认Prosigna获Medicare报销,引用CMS MolDX LCD L36125,覆盖生效日2026-08-19市场反应:10月16日盘前VCYT涨约1.9%至45.22美元,盘前量极低
- Investing.com同日13:20 UTC转发公司声明,标注AI生成、编辑审核
关键理由
- Medicare报销是LDT放量的关键前提,Prosigna 6月才上市、覆盖刚落地,对应美国早期ER阳性乳腺癌绝经后人群的新增可及市场
- 公司处于15%收入增长轨道,乳腺癌是其甲状腺/前列腺之外的新增长曲线,报销落地叠加2026 ASCO III期数据提升医生采纳信心
主要风险
- 覆盖生效日为8月19日,LCD此前已公开,今日仅为公司宣传性公告,存在预期差不足风险
- 未披露报销费率与患者量级,短期收入贡献小;盘前低量上涨约1.9%,若开盘高开过多易冲高回落
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-16 · 影响 weakens
LCD生效日8月19日意味着政策本身非当日新增,且乳腺癌ROR赛道面临Exact Sciences Oncotype DX等成熟竞争;未发现公司否认或利空,属削弱预期差而非证伪
检索:Veracyte Prosigna risks Medicare LCD already public August 2026 coverage denial competition Oncotype DX 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足直接压低confidence至5并将仓位降为small、收紧追高上限至3%
方向:未取得锚点干净的对齐先例:Veracyte同类Medicare覆盖公告(如2026-05-15 TrueMRD膀胱癌检测、2024-06 Afirma GSC扩围)可作机制类比,但本轮未取得经首发锚点校验的日线反应数据,不用于定幅度。
涨幅量级:缺乏高相似对齐样本,tp采用诊断股支付准入催化的保守小幅度,不引用未经核实的数字
形态:无法确认见光死模式;诊断公司报销公告通常温和正向、靠后续检测量兑现
工具执行结果 · 成功 7 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`vcyt prosigna breast risk of recurrence test medicare coverage | veracyte prosigna medicare moldx palmetto gba coverage breast cancer`;结构化索引覆盖完整 72 小时;旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整),返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选,不能据此证明消息首发或不是重复;按当前事件继续正常研判。" - web_search 成功 doubao_search · 1,674 ms
豆包搜索结果(原始查询:Veracyte Prosigna Medicare MolDX coverage Palmetto GBA announcement;API SearchType:web) - web_search 成功 doubao_search · 1,532 ms
豆包搜索结果(原始查询:Veracyte "Prosigna" Medicare coverage press release October 2026;API SearchType:web) - stock_quote 成功 stock_tools HTTP · 5,233 ms
{ - web_search 成功 doubao_search · 2,201 ms
豆包搜索结果(原始查询:Veracyte Prosigna breast Medicare coverage "August 19" MolDX LCD;API SearchType:web) - web_search 成功 doubao_search · 2,642 ms
豆包搜索结果(原始查询:Veracyte stock reaction Medicare coverage announcement Afirma Decipher next day shares;API SearchType:web) - web_search 成功 doubao_search · 2,609 ms
豆包搜索结果(原始查询:Veracyte Medicare coverage press release 2025 Decipher prostate OR Afirma secures Medicare coverage site:investor.veracyte.com;API SearchType:web)
原文全文
展开原文 · 1,892 字
SOUTH SAN FRANCISCO - Veracyte Inc. (NASDAQ:VCYT) announced that its Prosigna Breast Risk of Recurrence test received coverage through Palmetto GBA’s MolDX program, according to a press release statement.
The coverage, effective August 19, applies to postmenopausal women with early-stage estrogen receptor positive breast cancer who meet Medicare criteria, including stage I or II disease with 0-3 positive lymph nodes. The test was launched in the U.S. in June.
Prosigna analyzes tumor biology to estimate the risk of breast cancer recurrence over 10 years. The test combines molecular information with clinical and pathological factors to help oncologists determine treatment plans, including whether chemotherapy may benefit patients.
The independent, randomized phase III OPTIMA trial, led by University College London and presented at ASCO in 2026, showed that for more than two-thirds of patients with clinically high-risk breast cancer, Prosigna-guided treatment could spare them chemotherapy without compromising outcomes.
"We are pleased that Medicare has taken this significant step to ensure access to Prosigna for physicians and their breast cancer patients to support personalized treatment decisions," said Marc Stapley, Veracyte’s chief executive officer.
The test is available as a laboratory-developed test through Veracyte’s CLIA-certified laboratory in San Diego. The company offers financial assistance or tailored payment plans for eligible uninsured and underinsured patients through the Veracyte Access Program.
Veracyte is a diagnostics company that develops molecular tests for cancer care. The company’s portfolio includes tests for thyroid, bladder, prostate, and breast cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
e7df733692· 2026-10-16 21:23 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前